Results 31 to 40 of about 5,109,346 (334)

Circular RNA CircEYA3 induces energy production to promote pancreatic ductal adenocarcinoma progression through the miR-1294/c-Myc axis

Molecular Cancer, 2021
Background Extensive studies have demonstrated the pivotal roles of circular RNAs (circRNAs) in the occurrence and development of different human cancers. However, the expression and regulatory roles of circRNAs in pancreatic ductal adenocarcinoma (PDAC)
Zeyin Rong, Si Shi, Zhen Tan, Jin Xu, Qingcai Meng, Jie Hua, Jiang Liu, Bo Zhang, Wei Wang, Xianjun Yu, Chen Liang   +10 more
doaj   +1 more source

ALDOA inhibits cell cycle arrest induced by DNA damage via the ATM-PLK1 pathway in pancreatic cancer cells

Cancer Cell International, 2021
Background ALDOA is a glycolytic enzyme found mainly in developing embryos, adult muscle and various malignant tumours, including pancreatic tumours. Our previous study revealed that ALDOA, an oncogene, can promote the proliferation and metastasis of ...
Haidi Chen, Zeng Ye, Xiaowu Xu, Yi Qin, Changfeng Song, Guixiong Fan, Haifeng Hu, Yuheng Hu, Xianjun Yu, Wensheng Liu, Shunrong Ji, Wenyan Xu   +11 more
doaj   +1 more source

Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma

Journal of Hematology & Oncology, 2020
Pancreatic ductal adenocarcinoma (PDAC) is a malignancy characterized by a poor prognosis and high mortality rate. Genetic mutations and altered molecular pathways serve as targets in precise therapy.
Yunzhen Qian, Yitao Gong, Zhiyao Fan, Guopei Luo, Qiuyi Huang, Shengming Deng, He Cheng, Kaizhou Jin, Quanxing Ni, Xianjun Yu, Chen Liu   +10 more
doaj   +1 more source

Pancreatic resection for pancreatic cancer [PDF]

HPB, 2006
Ductal pancreatic adenocarcinoma, the most frequent malignancy of the pancreas, is characterized by retroperitoneal and perineural infiltration, early formation of multiple metastases, and resistance to most of the treatment regimens currently available.
M E Martignoni, Helmut Friess, Markus W. Büchler, Jeannine Bachmann, Christoph W. Michalski   +4 more
openaire   +3 more sources

Radical antegrade modular pancreatosplenectomy (RAMPS) versus standard retrograde pancreatosplenectomy (SRPS) for resectable body and tail pancreatic adenocarcinoma: protocol of a multicenter, prospective, randomized phase III control trial (CSPAC-3)

Trials, 2023
Background Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy. Radical surgical resection offers the only potential cure. There is increasing agreement that radical antegrade modular pancreatosplenectomy (RAMPS) may benefit ...
Jialin Li, Si Shi, Jiang Liu, Chen Liang, Jie Hua, Qingcai Meng, Hang Xu, Miaoyan Wei, Bo Zhang, Jin Xu, Wei Wang, Xianjun Yu   +11 more
doaj   +1 more source

An age-group analysis on the efficacy of chemotherapy in older adult patients with metastatic biliary tract cancer: a Japanese cancer registry cohort study

BMC Gastroenterology, 2023
Background The effectiveness of chemotherapy in older adult patients with biliary tract cancer (BTC) remains to be established, despite the fact that the majority of patients diagnosed with BTC tend to be aged ≥ 70 years.
Takeru Hirao, Kenji Ikezawa, Toshitaka Morishima, Kazuma Daiku, Yusuke Seiki, Ko Watsuji, Yasuharu Kawamoto, Sena Higashi, Makiko Urabe, Yugo Kai, Ryoji Takada, Takuo Yamai, Kaori Mukai, Tasuku Nakabori, Hiroyuki Uehara, Isao Miyashiro, Kazuyoshi Ohkawa   +16 more
doaj   +1 more source

Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.

New England Journal of Medicine, 2013
BACKGROUND In a phase 1-2 trial of albumin-bound paclitaxel (nab-paclitaxel) plus gemcitabine, substantial clinical activity was noted in patients with advanced pancreatic cancer. We conducted a phase 3 study of the efficacy and safety of the combination
D. V. Von Hoff, T. Ervin, F. Arena, E. Chiorean, J. Infante, M. Moore, T. Seay, S. Tjulandin, W. Ma, M. Saleh, M. Harris, M. Reni, S. Dowden, D. Laheru, N. Bahary, R. Ramanathan, J. Tabernero, M. Hidalgo, D. Goldstein, E. Van Cutsem, Xinyu Wei, J. Iglesias, M. Renschler   +22 more
semanticscholar   +1 more source

KRAS mutation in pancreatic cancer.

Seminars in Oncology, 2021
Pancreatic cancer is a recalcitrant cancer with one of the lowest 5-year survival rates. A hallmark of pancreatic cancer is the prevalence of oncogenic mutation in the KRAS gene.
Ji Luo
semanticscholar   +1 more source

Role of tumor mutation burden-related signatures in the prognosis and immune microenvironment of pancreatic ductal adenocarcinoma

Cancer Cell International, 2021
Background High tumor mutation burden (TMB) has gradually become a sensitive biomarker for predicting the response to immunotherapy in many cancers, including lung, bladder and head and neck cancers.
Rong Tang, Xiaomeng Liu, Wei Wang, Jie Hua, Jin Xu, Chen Liang, Qingcai Meng, Jiang Liu, Bo Zhang, Xianjun Yu, Si Shi   +10 more
doaj   +1 more source

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.

New England Journal of Medicine, 2011
BACKGROUND Data are lacking on the efficacy and safety of a combination chemotherapy regimen consisting of oxaliplatin, irinotecan, fluorouracil, and leucovorin (FOLFIRINOX) as compared with gemcitabine as first-line therapy in patients with metastatic ...
T. Conroy, F. Desseigne, M. Ychou, O. Bouché, R. Guimbaud, Y. Bécouarn, A. Adenis, J. Raoul, S. Gourgou-Bourgade, C. de la Fouchardière, J. Bennouna, J. Bachet, F. Khemissa-Akouz, D. Péré-Vergé, C. Delbaldo, E. Assenat, B. Chauffert, P. Michel, C. Montoto-Grillot, M. Ducreux   +19 more
semanticscholar   +1 more source